New pill for gut disease passes first safety check in healthy volunteers

NCT ID NCT06255834

Completed Knowledge-focused Sponsor: Nanjing Immunophage Biotech Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new oral drug called IPG11406 in 66 healthy adults to see if it is safe and how the body processes it. The drug is designed to treat inflammatory bowel diseases like Crohn's disease and ulcerative colitis. Participants received either the drug or a placebo, and researchers monitored side effects and drug levels in the blood. This is a first step to see if the drug is safe enough to test in patients with the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IPG11406
What this could lead to: If successful, this could lead to a new oral treatment for inflammatory bowel diseases like Crohn's disease or ulcerative colitis.
What could go wrong: This is a very early Phase 1 trial in only 66 healthy people, not patients. It only tests safety and how the drug moves through the body, not whether it works for the disease. Many drugs fail in later stages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

inflammatory bowel disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLAMMATORY BOWEL DISEASES

Contacts and locations

Locations

Zhejiang Hospital

Hangzhou, Zhejiang, 310013, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.